[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-361304-105":59,"doc-detail-361304-en":135},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":128,"head_meta":130,"extra_data":132,"updated_unix":134},105,"en","real-world-comparison-of-abiraterone-acetate-versus-docetaxel-in-combination-with-androgen-deprivation-therapy-a-retrospective-cohort-study-from-vietnam","Real-World Comparison of Abiraterone Acetate Versus Docetaxel in Combination With Androgen Deprivation Therapy - A Retrospective Cohort Study From Vietnam","","Real-world effectiveness of docetaxel versus abiraterone with androgen deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC) remains uncertain due to limited direct randomized evidence, especially in developing settings. This retrospective cohort study evaluated 128 Vietnamese patients treated at Vietnam National Cancer Hospital (Jan 2021–Dec 2025). Abiraterone showed a higher 6-month deep PSA response, but overall survival and progression-free survival were comparable. Baseline PSA and 6-month PSA kinetics independently predicted worse outcomes, supporting PSA-guided risk stratification and monitoring.",{"@graph":69,"@context":127},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/real-world-comparison-of-abiraterone-acetate-versus-docetaxel-in-combination-with-androgen-deprivation-therapy-a-retrospective-cohort-study-from-vietnam/361304/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/real-world-comparison-of-abiraterone-acetate-versus-docetaxel-in-combination-with-androgen-deprivation-therapy-a-retrospective-cohort-study-from-vietnam/361304.png","ImageObject",300,407,{"name":92,"@type":93},"dhado","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119,123],{"name":110,"@type":111,"acceptedAnswer":112},"What is the main research question of this study?","Question",{"text":113,"@type":114},"The study compares the effectiveness of docetaxel versus abiraterone in combination with ADT for metastatic hormone-sensitive prostate cancer in a Vietnamese real-world setting, and evaluates prognostic factors for survival outcomes.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How was the study conducted and who were the participants?",{"text":118,"@type":114},"A retrospective cohort study included patients with mHSPC treated at Vietnam National Cancer Hospital between January 2021 and December 2025. Eligible patients received first-line ADT combined with either docetaxel or abiraterone acetate.",{"name":120,"@type":111,"acceptedAnswer":121},"Did abiraterone improve survival compared with docetaxel?",{"text":122,"@type":114},"No clear survival advantage was observed. Although abiraterone produced a deeper PSA response at 6 months, progression-free survival and overall survival were not significantly different between groups.",{"name":124,"@type":111,"acceptedAnswer":125},"Which factors predicted worse outcomes in this cohort?",{"text":126,"@type":114},"Higher baseline PSA (>100 ng/mL) and failure to achieve low PSA at 6 months (PSA>0.2 ng/mL) independently predicted worse progression-free survival, and 6-month PSA>0.2 ng/mL was also associated with worse overall survival.","https://schema.org",{"og:url":83,"og:type":129,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":131,"canonical":83},"index,follow",{"doc_id":133,"site_id":62},361304,1790186488,{"code":4,"msg":5,"data":136},{"doc_id":133,"user_id":137,"nickname":92,"user_avatar":138,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":139,"file_id":140,"file_url":141,"file_type":142,"file_size":143,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":144,"language":145,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":146,"faqs":147,"seo_title":148,"seo_description":67,"update_tm":149,"read_time":41,"preview_page_count":19,"preview_urls":150},5909893218464,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","| Real-World Comparison of Abiraterone Acetate Versus Docetaxel in Combination With Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective Cohort Study From Vietnam | Cancer Control Volume 33: 1–12 © The Author(s) 2026 Article reuse guidelines:\u003Cbr>[sagepub.com/journals-permissions](sagepub.com/journals-permissions)\u003Cbr>[DOI: 10.1177/10732748261481960](DOI: 10.1177/10732748261481960)\u003Cbr>[journals.sagepub.com/home/ccx](journals.sagepub.com/home/ccx)\u003Cbr>\u003Cbr>|\n| --- | --- |\n| Hang Nguyen1,2, Hoa Nguyen2 , Hau Xuan Nguyen1,2, Minh Truong2 , and Tri Ngo1 \u003Cbr>Abstract\u003Cbr>Introduction: The optimal choice between docetaxel and abiraterone in combination with androgen deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC) remains uncertain due to the lack of direct randomized trials. Real-world data, particularly from developing countries, are limited. This study aimed to compare the effectiveness of docetaxel versus abiraterone in combination with ADT and to identify prognostic factors associated with survival outcomesin a Vietnamese population. Methods: We conducted a retrospective cohort study of patients with mHSPC treated at Vietnam National Cancer Hospital between January 2021 and December 2025. Eligible patients received first-line ADT combined with either docetaxel or abiraterone acetate. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method and compared using the log-rank test. Cox proportional hazards models were applied to evaluate prognostic factors. Results: Baseline characteristics were generally comparable. Abiraterone was associated with a higher rate of deep prostate-specific antigen (PSA) response at 6 months (PSA≤0.2 ng/mL: 43.7%vs. 16.7%, p=0.002). After a median follow-up of 28.6 months, the median OS was 41.4 months in the docetaxel group and 44.6 months in the abiraterone group. Median PFS was 23.6 and 29.6 months, respectively, with no statistically significant differences between groups. In multivariable analysis, baseline PSA>100 ng/mL (HR 1.98, p=0.01, 95% CI: 1.15-3.42) and PSA>0.2 ng/mL at 6 months (HR 3.93, p\u003C0.001, 95% CI: 1.82-8.49) were independent predictors of worse PFS. PSA>0.2 ng/mL at 6 months was also associated with inferior OS (HR 2.66, p=0.03, 95% CI: 1.09-6.47) . Conclusion: In this real-world Vietnamese cohort, docetaxel andabiraterone combined with ADT provided comparable survival outcomes in mHSPC. Although abiraterone achieved deeper PSA responses, this did not translate into a survival advantage. Baseline PSA and 6-month PSA response were strong prognostic factors, underscoring the clinical value of PSA kinetics in risk stratification and treatment monitoring.\u003Cbr>Plain Language Summary\u003Cbr>Prostate cancer that has spread to other parts of the body is often treated with hormone therapy. In many patients, hormone therapy is combined with either docetaxel, a chemotherapy drug, or abiraterone, an oral medicine that further blocks male hormone production. However, it is still unclear which option works better in routine clinical practice, especially in developing countries. This study reviewed 128Vietnamese patients with metastatic hormone-sensitive prostate cancer who were treated at Vietnam National Cancer Hospital between 2021 and 2025. All patients received hormone therapy together with either docetaxel or abiraterone. Patients treated with abiraterone were more likely to have a very deep decline in |  |\n| 1Department of Oncology, Hanoi Medical University, Hanoi, Vietnam\u003Cbr>2Department of Medical Oncology, Vietnam National Cancer Hospital, Hanoi, Vietnam\u003Cbr>Corresponding author:\u003Cbr>Tri Ngo, Department of Oncology, Hanoi Medical University, No.1 Ton That Tung str., Kim Lien, Hanoi, 100000, Vietnam.\u003Cbr>Email: [ngominhtri.md@gmail.com](ngominhtri.md@gmail.com) |  |\n\nCreative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons  \nAttr","cbCaic5Z0XMgFKY0","https://ap.wps.com/l/cbCaic5Z0XMgFKY0","pdf",2004994,12,"English","# Abstract\n## Introduction\n## Methods\n## Results\n## Conclusion\n## Plain Language Summary\n## Keywords","[{\"question\":\"What is the main research question of this study?\",\"answer\":\"The study compares the effectiveness of docetaxel versus abiraterone in combination with ADT for metastatic hormone-sensitive prostate cancer in a Vietnamese real-world setting, and evaluates prognostic factors for survival outcomes.\"},{\"question\":\"How was the study conducted and who were the participants?\",\"answer\":\"A retrospective cohort study included patients with mHSPC treated at Vietnam National Cancer Hospital between January 2021 and December 2025. Eligible patients received first-line ADT combined with either docetaxel or abiraterone acetate.\"},{\"question\":\"Did abiraterone improve survival compared with docetaxel?\",\"answer\":\"No clear survival advantage was observed. Although abiraterone produced a deeper PSA response at 6 months, progression-free survival and overall survival were not significantly different between groups.\"},{\"question\":\"Which factors predicted worse outcomes in this cohort?\",\"answer\":\"Higher baseline PSA (\\u003e100 ng/mL) and failure to achieve low PSA at 6 months (PSA\\u003e0.2 ng/mL) independently predicted worse progression-free survival, and 6-month PSA\\u003e0.2 ng/mL was also associated with worse overall survival.\"}]","Real-World Comparison of Abiraterone Acetate Versus Docetaxel in Combination With Androgen Deprivation Therapy - A Retrospective Cohort Study From Vietnam | PDF",1790143879,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b443d4f29b469dd86b4fbdcdd5aa04af.webp",983,1310,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fad6f49d5aec4c8f4133d7e597353e30.webp",982,1309,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0cf29f88d19a3b465c50359ef74fc5b1.webp",981,1308,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/25af9bba27d7f10fbd825b62b956c0f7.webp",980,1306]